E1690: ECOG E1690 Trial
In hdbayes: Bayesian Analysis of Generalized Linear Models with Historical Data
E1690 R Documentation
ECOG E1690 Trial
Description
A data set from the ECOG E1690 trial evaluating the effectiveness of the interferon alfa-2b
(IFN) therapy compared to the observation in high-risk melanoma patients. There were three
arms in the trial: high-dose IFN, low-dose IFN, and observation. The study results were
described in Kirkwood et al. (2000) doi:10.1200/JCO.2000.18.12.2444. Here, we only consider
the high-dose IFN arm and the observation arm so that this data set has the same variables as
the E1684 data set. We can use the E1684 data as the historical data and the E1690 data as the
current data.
Usage
E1690
Format
A data frame with 426 rows and 8 variables:
- failtime
time to relapse in years
- failcens
censoring indicator for time to relapse, 0 = did not relapse, 1 = relapsed
- survtime
time to death in years
- survcens
censoring indicator for time to death, 0 = alive, 1 = dead
- treatment
treatment indicator, 0 = observation, 1 = high-dose IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- node_bin
indicator for having more than one cancerous lymph node,
0 = with one or no cancerous lymph nodes,
1 = with more than one cancerous lymph node
References
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., and Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. Journal of Clinical Oncology, 18(12), 2444–2458.
hdbayes documentation built on Sept. 11, 2024, 5:34 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| E1690 | R Documentation |
ECOG E1690 Trial
Description
A data set from the ECOG E1690 trial evaluating the effectiveness of the interferon alfa-2b (IFN) therapy compared to the observation in high-risk melanoma patients. There were three arms in the trial: high-dose IFN, low-dose IFN, and observation. The study results were described in Kirkwood et al. (2000) doi:10.1200/JCO.2000.18.12.2444. Here, we only consider the high-dose IFN arm and the observation arm so that this data set has the same variables as the E1684 data set. We can use the E1684 data as the historical data and the E1690 data as the current data.
Usage
E1690
Format
A data frame with 426 rows and 8 variables:
- failtime
time to relapse in years
- failcens
censoring indicator for time to relapse, 0 = did not relapse, 1 = relapsed
- survtime
time to death in years
- survcens
censoring indicator for time to death, 0 = alive, 1 = dead
- treatment
treatment indicator, 0 = observation, 1 = high-dose IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- node_bin
indicator for having more than one cancerous lymph node, 0 = with one or no cancerous lymph nodes, 1 = with more than one cancerous lymph node
References
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., and Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. Journal of Clinical Oncology, 18(12), 2444–2458.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.